BioTime公司今日早前宣布计划收购一家新加坡私营有限责任公司胚胎干细胞国际公司（ES Cell International Pte Ltd，ESI）。BioTime在今日早前公布的新闻发布中表示，公司将"收购ESI的全部约3500万美元债款及应计利息。除BioTime在收购完成后将要承担的偿付义务之外，ESI不 ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design ...

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today ...

BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTIM) today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...

BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...

MADISON - BioTime, Inc. (OTCBB: BTIM) has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for 173 patents and patent applications relating to human embryonic stem ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares ...